These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31658420)

  • 1. Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
    Steinmetzer T; Pilgram O; Wenzel BM; Wiedemeyer SJA
    J Med Chem; 2020 Feb; 63(4):1445-1472. PubMed ID: 31658420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.
    Al-Horani RA; Desai UR
    Med Res Rev; 2014 Nov; 34(6):1168-216. PubMed ID: 24659483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Termination of bleeding by a specific, anticatalytic antibody against plasmin.
    Zhao T; Houng A; Reed GL
    J Thromb Haemost; 2019 Sep; 17(9):1461-1469. PubMed ID: 31136076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of inhibitors of fibrinolysis.
    Verstraete M
    Drugs; 1985 Mar; 29(3):236-61. PubMed ID: 2580684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition.
    Anonick PK; Vasudevan J; Gonias SL
    Arterioscler Thromb; 1992 Jun; 12(6):708-16. PubMed ID: 1375508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.
    Longstaff C
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):537-42. PubMed ID: 7531000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors.
    Swedberg JE; Harris JM
    Biochemistry; 2011 Oct; 50(39):8454-62. PubMed ID: 21877690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
    Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E
    FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.
    Vadivel K; Kumar Y; Ogueli GI; Ponnuraj SM; Wongkongkathep P; Loo JA; Bajaj MS; Bajaj SP
    J Thromb Haemost; 2016 Dec; 14(12):2509-2523. PubMed ID: 27797450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.
    Mathews II; Vanderhoff-Hanaver P; Castellino FJ; Tulinsky A
    Biochemistry; 1996 Feb; 35(8):2567-76. PubMed ID: 8611560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen-plasmin system IX. Specific binding of tranexamic acid to plasmin.
    Iwamoto M
    Thromb Diath Haemorrh; 1975 Jun; 33(3):573-85. PubMed ID: 125463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
    Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
    J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current place of aprotinin in the management of bleeding.
    Royston D
    Anaesthesia; 2015 Jan; 70 Suppl 1():46-9, e17. PubMed ID: 25440394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Evaluation of Anti-Fibrinolytic Plasmin Inhibitors Derived from 5-(4-Piperidyl)isoxazol-3-ol (4-PIOL).
    Schmidt TC; Eriksson PO; Gustafsson D; Cosgrove D; Frølund B; Boström J
    J Chem Inf Model; 2017 Jul; 57(7):1703-1714. PubMed ID: 28653850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding.
    Rahman MN; Petrounevitch V; Jia Z; Koschinsky ML
    Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.
    Bajaj MS; Ogueli GI; Kumar Y; Vadivel K; Lawson G; Shanker S; Schmidt AE; Bajaj SP
    J Biol Chem; 2011 Feb; 286(6):4329-40. PubMed ID: 21115497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmin: A Modulator of Immune Function.
    Draxler DF; Sashindranath M; Medcalf RL
    Semin Thromb Hemost; 2017 Mar; 43(2):143-153. PubMed ID: 27677178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives.
    Rabadà Y; Bosch-Sanz O; Biarnés X; Pedreño J; Caveda L; Sánchez-García D; Martorell J; Balcells M
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basis of antifibrinolytic therapy.
    Prentice CR
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():35-40. PubMed ID: 6159375
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors.
    Komorowicz E; Kolev K; Machovich R
    Biochemistry; 1998 Jun; 37(25):9112-8. PubMed ID: 9636057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.